A flat rate that names its exceptions
The homepage prices semaglutide and tirzepatide as one flat monthly figure each, states that the figure covers the doctor, the medication and shipping, and then says the price is flat at every standard dose before listing the two doses where it is not. Both exception figures are printed.
Most flat-rate claims in this category are silent about the dose at which they stop being true. Publishing the counterexample beside the claim is the behaviour of a seller expecting to be read carefully, and it is the strongest thing on the site.
The unit contradiction
The maximum-dose semaglutide exception is stated per month on the homepage and per four weeks on the semaglutide page. Those are different prices. Thirteen four-week cycles fit in a year and twelve months do not, so the same figure under the second reading costs roughly a month more per year than under the first.
Because the site names both units for one figure, this page does not assert either. The exception row carries no per-month suffix, and the contradiction is recorded in the row rather than resolved by guesswork. The base rates, which are stated consistently as monthly on every page, are recorded as monthly.
Dose increases are not automatic
The site states that dose increases require physician approval and that a patient reviews and confirms any price change before it takes effect. Combined with the published exceptions, that means the two doses where the bill changes are both named in advance and gated by consent.
It also publishes a refund position in plain words: a full refund if treatment is not approved, and a stated point after which payment becomes non-refundable because the compounded medication has been prepared for that patient. That is the kind of clause usually left to a terms page.
A second pair of numbers that disagree
The homepage hero and the programme cards state different prices for the phentermine programme. It is not a GLP-1 product and no price row is recorded for it here, but it is the second place on one site where two numbers describe one thing.
Beyond that, the usual gaps: the compounding pharmacy is described by licensing class rather than named, no state list appears anywhere we read, and no individual prescribing clinician or medical director is identified.
TeleDocs360's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $299/moper month, flat at every standard dose; the page states the figure covers the doctor, the medication and shipping | September 2026source |
| Semaglutide (compounded) | $349the stated exception to the flat rate; the homepage calls this figure $349/month and the semaglutide page calls the same figure $349/4-weeks, so the site names two different units for it and no per-month suffix is asserted here | September 2026source |
| Tirzepatide (compounded) | $399/moper month, flat at every standard dose; the page states the figure covers the doctor, the medication and shipping | September 2026source |
| Tirzepatide (compounded) | $649/moper month at the two advanced doses, stated on the homepage as the second exception to the flat rate | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See TeleDocs360's current price →Good fit if
- Readers who want a flat rate with its exceptions printed rather than discovered at a dose increase.
- Patients who want the doctor, medication and shipping stated as covered by one figure.
- Anyone who wants dose changes gated by explicit confirmation before a price moves.
- Readers who want a refund position stated in plain language on the page they are buying from.
Look elsewhere if
- Anyone budgeting to the maximum semaglutide dose, where the site names two different units for the same figure.
- Readers who need the compounding pharmacy named.
- Patients who must confirm their state is served before starting.
- Anyone who wants a brand-name, FDA-approved GLP-1; everything here is compounded.
How this review was verified
- Read the homepage and the semaglutide programme page at their source URLs and logged each figure with the date it was read.
- Recorded the base rate for each molecule as monthly, since every page states it in months consistently.
- Recorded the maximum-dose semaglutide exception without a per-month suffix, because the homepage calls it a monthly figure and the semaglutide page calls the same figure a four-week one.
- Recorded the disagreement between the homepage hero and the programme cards on a non-GLP-1 product as a second instance of the same defect, without filing a price row for it.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter for the brand or the operating company.